

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=381	N
Age	67.3 (10.9)	381
Sex: Men	239 (62.7%)	381
Tumor level:		381
0-6cm	126 (33.1%)	
7-12cm	212 (55.6%)	
13-15cm	43 (11.3%)	
Tumor stage:		381
0	39 (10.2%)	
I	116 (30.4%)	
II	102 (26.8%)	
III	124 (32.5%)	
Neoadjuvant treatment	173 (45.4%)	381
Type of resection:		381
Abdominoperineal resection	72 (18.9%)	
Anterior resection	274 (71.9%)	
Hartmann	35 (9.19%)	
Perforation	19 (4.99%)	381
Invasion circumferential margin	28 (7.35%)	381
Mesorecto quality:		377
Satisfactory	277 (73.5%)	
Partial	58 (15.4%)	
No-satisfactory	42 (11.1%)	
Recidive	7 (1.84%)	381
Months to recidive	32.0 [13.0;59.0]	381
Metastasis	51 (13.4%)	381
Months to Metastasis	27.0 [11.0;58.0]	381
Exitus	61 (16.0%)	381
Months to exitus	32.0 [14.0;59.0]	381


Table 2: According to Local Recurrence

	No event n= 374	Event n= 7	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.72 (1.09)	7.20 (1.08)	1.80 [0.81;3.98]	0.148	1.54 [0.68; 3.47]	0.3
Sex: Men	235 (62.8%)	4 (57.1%)	0.84 [0.19;3.76]	0.822	0.84 [0.12; 5.80]	0.862
Tumor level:						
0-6cm	124 (33.2%)	2 (28.6%)	0.74 [0.07;8.20]	0.809	0.07 [0.00; 4.63]	0.214
7-12cm	208 (55.6%)	4 (57.1%)	0.96 [0.11;8.59]	0.971	0.56 [0.04; 7.80]	0.668
Tumor stage:						
0	39 (10.4%)	0 (0.00%)	1.00 [0.00;.]	1.000	0.37 [0.00; Inf]	1
II	100 (26.7%)	2 (28.6%)	314090654 [0.00;.]	0.999	183149352.13 [0.00; Inf]	0.999
III	119 (31.8%)	5 (71.4%)	689047926 [0.00;.]	0.999	574958371.32 [0.00; Inf]	0.999
Neoadjuvant treatment	169 (45.2%)	4 (57.1%)	2.03 [0.45;9.08]	0.354	8.38 [0.85; 82.26]	0.068
Type of resection:						
Abdominoperineal resection	69 (18.4%)	3 (42.9%)	4.23 [0.85;21.0]	0.078	9.49 [0.35;256.80]	0.181
Hartmann	34 (9.09%)	1 (14.3%)	2.80 [0.29;27.0]	0.372	1.59 [0.12; 20.14]	0.722
Perforation	17 (4.55%)	2 (28.6%)	7.07 [1.37;36.5]	0.019	8.27 [0.62;110.23]	0.11
Invasion circumferential margin	25 (6.68%)	3 (42.9%)	9.75 [2.18;43.6]	0.003	8.58 [1.41; 52.28]	0.02
Mesorrecto quality:						
Partial	56 (15.1%)	2 (28.6%)	2.80 [0.51;15.3]	0.235	2.21 [0.29; 16.64]	0.443
No-satisfactory	41 (11.1%)	1 (14.3%)	2.21 [0.25;19.8]	0.480	0.95 [0.06; 16.14]	0.97

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	381	290	210	182	141	93


Table 3: According to Metastasis

	No event n= 330	Event n= 51	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.72 (1.06)	6.76 (1.27)	1.13 [0.87;1.47]	0.361	0.94 [0.72; 1.23]	0.658	381
Sex: Men	210 (63.6%)	29 (56.9%)	0.84 [0.48;1.46]	0.538	0.87 [0.50; 1.54]	0.64	381
Tumor level:							381
0-6cm	112 (33.9%)	14 (27.5%)	0.85 [0.33;2.22]	0.741	0.50 [0.13; 1.88]	0.303	
7-12cm	181 (54.8%)	31 (60.8%)	1.22 [0.51;2.93]	0.651	1.34 [0.55; 3.28]	0.522	
Tumor stage:							381
0	37 (11.2%)	2 (3.92%)	0.86 [0.18;4.06]	0.850	0.76 [0.16; 3.75]	0.74	
II	90 (27.3%)	12 (23.5%)	1.75 [0.71;4.27]	0.222	1.66 [0.66; 4.18]	0.279	
III	95 (28.8%)	29 (56.9%)	3.86 [1.76;8.44]	0.001	3.09 [1.36; 7.05]	0.007	
Neoadjuvant treatment	150 (45.5%)	23 (45.1%)	1.16 [0.67;2.01]	0.600	1.33 [0.69; 2.57]	0.388	381
Type of resection:							381
Abdominoperineal resection	59 (17.9%)	13 (25.5%)	2.07 [1.07;4.02]	0.031	3.55 [1.12;11.27]	0.031	
Hartmann	24 (7.27%)	11 (21.6%)	3.36 [1.67;6.77]	0.001	2.88 [1.32; 6.29]	0.008	
Perforation	14 (4.24%)	5 (9.80%)	2.12 [0.84;5.33]	0.111	2.08 [0.76; 5.65]	0.151	381
Invasion circumferential margin	19 (5.76%)	9 (17.6%)	2.96 [1.44;6.09]	0.003	1.94 [0.89; 4.24]	0.094	381
Mesorecto quality:							377
Partial	53 (16.3%)	5 (9.80%)	0.64 [0.25;1.63]	0.353	0.50 [0.19; 1.30]	0.153	
No-satisfactory	37 (11.3%)	5 (9.80%)	1.04 [0.41;2.64]	0.933	0.93 [0.34; 2.52]	0.886	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	381	275	195	165	132	88

Table 4: According to Exitus


	No event n= 320	Event n= 61	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.61 (1.06)	7.38 (1.02)	2.26 [1.69;3.01]	<0.001	1.93 [1.40;2.64]	<0.001	381
Sex: Men	195 (60.9%)	44 (72.1%)	1.66 [0.95;2.90]	0.078	1.72 [0.96;3.07]	0.067	381
Tumor level:							381
0-6cm	100 (31.2%)	26 (42.6%)	2.43 [0.85;6.96]	0.098	1.71 [0.50;5.81]	0.392	
7-12cm	181 (56.6%)	31 (50.8%)	1.85 [0.65;5.24]	0.247	1.50 [0.51;4.42]	0.461	
Tumor stage:							381
0	37 (11.6%)	2 (3.28%)	0.37 [0.09;1.60]	0.183	0.33 [0.07;1.43]	0.138	
II	89 (27.8%)	13 (21.3%)	0.78 [0.39;1.59]	0.500	0.85 [0.41;1.79]	0.671	
III	97 (30.3%)	27 (44.3%)	1.43 [0.79;2.57]	0.237	1.03 [0.54;1.97]	0.918	
Neoadjuvant treatment	145 (45.3%)	28 (45.9%)	1.24 [0.75;2.05]	0.406	1.75 [0.97;3.15]	0.064	381
Type of resection:							381
Abdominoperineal resection	54 (16.9%)	18 (29.5%)	2.63 [1.46;4.73]	0.001	1.36 [0.60;3.10]	0.467	
Hartmann	21 (6.56%)	14 (23.0%)	3.93 [2.08;7.44]	<0.001	2.44 [1.18;5.01]	0.016	
Perforation	14 (4.38%)	5 (8.20%)	1.54 [0.62;3.86]	0.352	1.28 [0.50;3.30]	0.61	381
Invasion circumferential margin	18 (5.62%)	10 (16.4%)	2.57 [1.31;5.07]	0.006	2.15 [0.99;4.66]	0.052	381
Mesorrecto quality:							377
Partial	47 (14.9%)	11 (18.0%)	1.44 [0.74;2.80]	0.279	1.01 [0.50;2.05]	0.976	
No-satisfactory	34 (10.8%)	8 (13.1%)	1.72 [0.81;3.67]	0.160	1.18 [0.53;2.61]	0.69	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	381	291	212	183	143	94

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	72	55	35	28	25	13
Ant	274	218	161	138	107	73
H	35	27	21	17	13	7

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	72	51	32	23	21	12
Ant	274	209	150	126	99	69
H	35	23	20	17	14	7

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	72	55	36	28	25	13
Ant	274	218	162	138	107	73
H	35	27	21	18	14	8

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	0.63 [1.51; 0]	6.52 [9.12; 3.84]	5.07 [7.33; 2.75]
24	1.33 [2.62; 0.02]	12.78 [16.57; 8.83]	12.06 [15.69; 8.27]
36	1.85 [3.47; 0.19]	16.65 [21.06; 11.99]	14.23 [18.21; 10.05]
48	2.52 [4.6; 0.4]	17.71 [22.28; 12.87]	18.75 [23.43; 13.79]
60	3.27 [5.79; 0.7]	20.07 [25.18; 14.6]	25.39 [31.11; 19.2]